Browse drugs

…ow (see section on Current treatments). The antifibrotic drugs, pirfenidone and nintedanib, are established treatments for idiopathic pulmo…

… (39.4%), deranged liver function (9.2%) and weight loss (5.7%).Nintedanib was discontinued in 27 patients and was due to diarrhoea 38.4%,…

…nib vs traditional drugs mechanism, IDDF2026-ABS-0129 Figure 2. Nintedanib efficacy in IBD fibrosis).Conclusions In the DSS-induced mouse …

…otrexate and Sulfasalazine as well as biological agents such as Adalimumab and Rituximab. Here, we therefore compare real-world experience…

…–5 years from symptom onset. Antifibrotic agents–nintedanib and pirfenidone–slow disease progression and may extend survival. However, real…

… of 22.2 months (95% CI 18.1-26.2), 51% of patients interrupted nintedanib due to diarrhoea (33%), nausea/vomiting (21%), reflux (2%), wei…

…Objective Nintedanib is approved for the treatment of interstitial lung disease (ILD…

… of 22.2 months (95% CI 18.1–26.2), 51% of patients interrupted nintedanib due to diarrhoea (33%), nausea/vomiting (21%), reflux (2%), wei…

…Background Pirfenidone and Nintedanib are antifibrotic medications licensed in the UK for Idopathetic…

…ing outside of routine schedules either related or unrelated to Nintedanib treatment, necessitating treatment breaks or stopping treatment…

…density over 52 weeks with placebo, but it remained stable with nintedanib. Among patients who had ILD progression (n=11), there was a num…

…tion and delayed dose reduction, suggesting improved adherence. Pirfenidone was associated with a higher rate of treatment discontinuation.…